Core Viewpoint - The company Baiyunshan (00874.HK) has announced a share acquisition agreement with an independent third party, Haizheng Pharmaceutical, for the purchase of 100% equity in the target company, Zhejiang Yigong, for approximately RMB 500 million [1] Group 1 - The buyer, a subsidiary of the company, Guangzhou Pharmaceutical, will acquire 100% equity of the target company upon completion of the transaction [1] - The target company, Zhejiang Yigong, is a pharmaceutical distribution enterprise based in Zhejiang Province, primarily engaged in the wholesale of various pharmaceutical products [1]

Core Viewpoint - The SPD (Supply, Processing, Distribution) concept sector is experiencing significant market activity, with multiple stocks reaching their daily limit up, driven by the demand for upgraded pharmaceutical supply chain management services [1][2]. Group 1: Stock Performance - The SPD concept sector saw three stocks hit the daily limit up, including 华人健康 (China Health) at 20% increase, 英特集团 (Yingte Group) at 10.02%, and 塞力医疗 (Saili Medical) at 9.99% [1][2]. - Other notable performers include 漱玉平民 (Shuyupingmin) with an 11.78% increase, 思创医惠 (Sichuang Medical) at 9.13%, and 达嘉维康 (Dajia Weikang) at 8.40% [1][2]. Group 2: Market Dynamics - The core logic behind the market's interest in the SPD concept is the increasing demand for pharmaceutical supply chain management services, driven by policies aimed at controlling medical insurance costs and improving pharmaceutical distribution efficiency [1][3]. - The SPD model integrates procurement, warehousing, distribution, and settlement processes, helping medical institutions reduce operational costs and optimize inventory management, thus enhancing transparency and efficiency in the flow of pharmaceuticals and consumables [1][3]. Group 3: Impacted Sectors - The promotion of the SPD model is expected to reshape the pharmaceutical distribution industry, allowing companies with SPD service qualifications and resource advantages to expand their client base among medical institutions, transitioning from traditional distribution to full-process services, thereby increasing revenue scale and gross margins [3]. - The medical information technology sector will benefit from the SPD system's reliance on digital platforms, with companies providing medical supply chain information solutions likely to receive more orders, positioning technology leaders favorably in market competition [3]. - In the medical device consumables sector, the SPD model will lead to more centralized and efficient procurement and distribution, allowing production companies that collaborate closely with SPD service providers to reduce distribution costs and secure stable hospital channel orders, enhancing market share and profitability [3].

12月17日，白云山（600332）及其在新三板挂牌的控股子公司广州医药(874839)分别发布公告称，广州 医药拟受让浙江省医药工业有限公司（以下称"浙江医工"）100%股权，转让价款为5.01亿元。本次交易 尚需中国反垄断审查机构进行经营者集中审查，存在不确定性。 根据公告，为进一步优化广州医药在华东区域的产业布局，推动广州医药业务发展，经白云山董事会战 略发展与投资委员会2025年第十次会议审议，同意广州医药通过公开摘牌的方式参与海正药业 （600267）转让其持有的全资子公司浙江医工100%股权事宜。2025年12月10日，广州医药以5.01亿元 的价格成功摘牌，并向台州市产权交易所有限公司缴纳竞买保证金8600万元。广州医药与海正药业规范 已于12月17日签署了《浙江省医药工业有限公司股权交易合同》及《浙江省医药工业有限公司股权交易 合同之补充协议》，本次交易的资金来源为广州医药自有资金，交易完成后，广州医药将持有浙江医工 100%股权。 据介绍，浙江医工是浙江省医药流通企业，拥有浙江省麻黄素、咖啡因及二类麻醉药品的经营及配送资 质，其配送网络覆盖浙江全省，业务以医院纯销及药店批发为主。 公告称，浙 ...

南财智讯12月18日电，白云山（00874.HK）发布须予披露交易公告，于2025年12月17日，公司子公司 广州医药股份有限公司与浙江海正药业股份有限公司订立《股权交易合同》，拟通过公开挂牌方式收购 浙江省医药工业有限公司100%股权，交易对价为人民币5.005亿元。其中8600万元已作为竞买保证金支 付并转为部分对价，剩余4.145亿元将在合同生效后五个工作日内一次性支付至台州市产权交易所有限 公司指定账户。本次交易构成白云山的须予披露交易，但未达到股东批准标准。目标公司为浙江省排名 前六的优质医药流通企业，最近一年销售收入超40亿元，收购有助于广州医药完善华东区域布局，提升 终端市场覆盖能力。本次收购资金来源于广州医药自有资金，董事会认为交易条款公平合理，不会对公 司财务及经营状况产生不利影响，符合公司及股东整体利益。 ...

Core Viewpoint - The acquisition of 100% equity in Zhejiang Pharmaceutical Industry Co., Ltd. by Guangzhou Pharmaceutical is a strategic move to enhance market presence in the East China region, with a transaction value of RMB 500 million [1] Group 1: Acquisition Details - Guangzhou Pharmaceutical, a subsidiary of the company, has entered into a share purchase agreement to acquire 100% equity of Zhejiang Pharmaceutical from Haizheng Pharmaceutical for RMB 500 million [1] - The acquisition is set to be completed by December 17, 2025, after which Guangzhou Pharmaceutical will hold full ownership of the target company [1] Group 2: Target Company Overview - Zhejiang Pharmaceutical is a leading pharmaceutical distribution enterprise in Zhejiang Province, primarily engaged in the wholesale of various pharmaceutical products [1] - The company reported annual sales revenue exceeding RMB 4 billion in the past year, indicating a strong growth potential [1] Group 3: Strategic Rationale - The acquisition price reflects a premium over the assessed value, which the company considers reasonable based on several factors [1] - The target company is ranked among the top six pharmaceutical distribution enterprises in Zhejiang, providing a well-established customer network and market presence [1] - This acquisition will enable Guangzhou Pharmaceutical to optimize its industrial layout in East China and enhance coverage in the domestic terminal market [1]

白云山（600332）(00874)公布，于2025年12月17日，买方(广州医药，公司子公司)与卖方(海正药业 （600267），公司独立第三方)订立了股权交易合同及补充协议。根据股权交易合同及补充协议，买方 拟收购浙江省医药工业有限公司100%股权，收购对价为约人民币5.005亿元。于收购事项完成后，买方 将持有目标公司100%股权。 公告称，目标公司位于长三角地区，医药市场发达，是浙江省排名前六的优质医药流通企业。目标公司 长期深耕浙江省市场，积累了丰富的客户资源，最近一年年销售收入规模超过人民币40亿元，具有良好 发展前景;收购事项有利于广州医药获取浙江省及周边地区成熟的客户网络，进一步优化在华东区域的 产业佈布局，提升对国内终端市场的覆盖广度和深度。 ...

智通财经APP讯，白云山(00874)公布，于2025年12月17日，买方(广州医药，公司子公司)与卖方(海正药 业，公司独立第三方)订立了股权交易合同及补充协议。根据股权交易合同及补充协议，买方拟收购浙 江省医药工业有限公司100%股权，收购对价为约人民币5.005亿元。于收购事项完成后，买方将持有目 标公司100%股权。 公告称，目标公司位于长三角地区，医药市场发达，是浙江省排名前六的优质医药流通企业。目标公司 长期深耕浙江省市场，积累了丰富的客户资源，最近一年年销售收入规模超过人民币40亿元，具有良好 发展前景;收购事项有利于广州医药获取浙江省及周边地区成熟的客户网络，进一步优化在华东区域的 产业佈布局，提升对国内终端市场的覆盖广度和深度。 ...

Core Viewpoint - The acquisition of 100% equity in Zhejiang Pharmaceutical Industry Co., Ltd. by Guangzhou Pharmaceutical is a strategic move to enhance market presence in the East China region, with a transaction value of RMB 500 million [1] Group 1: Acquisition Details - Guangzhou Pharmaceutical, a subsidiary of the company, has entered into a share purchase agreement to acquire 100% equity of Zhejiang Pharmaceutical from Haizheng Pharmaceutical for RMB 500 million [1] - The acquisition is set to be completed by December 17, 2025, after which Guangzhou Pharmaceutical will hold full ownership of the target company [1] Group 2: Target Company Overview - Zhejiang Pharmaceutical is a leading pharmaceutical distribution enterprise in Zhejiang Province, primarily engaged in the wholesale of various pharmaceutical products [1] - The company reported annual sales revenue exceeding RMB 4 billion in the past year, indicating a strong growth potential [1] Group 3: Strategic Rationale - The acquisition price reflects a premium over the assessed value, which the company considers reasonable based on several factors [1] - The target company is ranked among the top six pharmaceutical distribution enterprises in Zhejiang, providing a well-established customer network and market presence [1] - This acquisition will enable Guangzhou Pharmaceutical to optimize its industrial layout in East China and enhance coverage in the domestic terminal market [1]

北京商报讯（记者 丁宁）12月17日晚间，白云山（600332）发布公告称，公司下属控股子公司广州医 药拟通过公开摘牌方式受让海正药业所持浙江省医药工业有限公司（以下简称"浙江医工"）100%股 权，转让价款为5.01亿元。 白云山表示，本次交易有利于广州医药获得浙江省及周边地区成熟的客户网络，进一步优化广州医药在 华东区域的产业布局，提升对国内终端市场的覆盖广度和深度，符合公司及广州医药长远发展的战略规 划。 资料显示，浙江医工是浙江省医药流通企业，拥有浙江省麻黄素、咖啡因及二类麻醉药品的经营及配送 资质，其配送网络覆盖浙江全省，业务以医院纯销及药店批发为主。 ...

智通财经APP讯，白云山(600332.SH)发布公告，公司下属控股子公司广州医药拟通过公开摘牌方式受 让海正药业所持浙江省医药工业有限公司("浙江医工")100%股权，转让价款为5.01亿元。 浙江医工地处长三角地区，医药市场发达，且是浙江省排名前6的优质医药流通企业。同时，浙江医工 一直深耕浙江省医药市场，积累了丰富的客户资源，最近一年年销售收入规模40亿元以上，拥有良好的 前景。本次交易有利于广州医药获得浙江省及周边地区成熟的客户网络，进一步优化广州医药在华东区 域的产业布局，提升对国内终端市场的覆盖广度和深度，符合公司及广州医药长远发展的战略规划。 ...